Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239303575> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4239303575 endingPage "431" @default.
- W4239303575 startingPage "427" @default.
- W4239303575 abstract "Study Objective: Glucagon is a rapid-acting smooth muscle relaxant with a short half-life. Previous studies suggested glucagon may have bronchodilator effects. We sought to determine whether intravenous glucagon produces clinically important immediate bronchodilation in emergency department patients with asthma exacerbation. Methods: We conducted a randomized, double-blind, placebo-controlled study at 2 university-affiliated community teaching hospital EDs (annual census 90,000). ED patients 18 to 50 years old with asthma exacerbation and peak expiratory flow rate (PEFR) less than 350 L/min were eligible. Exclusion criteria were need for intubation, chronic obstructive pulmonary disease, diabetes mellitus, insulinoma, pheochromocytoma, pregnancy, lactation, or current oral steroid treatment. Patients were randomly assigned to receive glucagon 0.03 mg/kg or an equivalent volume of saline solution intravenously. At 10 minutes, PEFR was measured and all patients began standardized albuterol therapy. Successful bronchodilation was a PEFR increase of 60 L/min at 10 minutes. Results: Success occurred in 2 (9.5%) of 21 glucagon-treated patients and 3 (12%) of 25 placebo-treated patients (95% confidence interval [CI] for difference of –2.5% [–20.4% to 15.4%]). Mean PEFR improvement for glucagon was 2 L/min versus 9 L/min for placebo (95% CI for difference of –7 L/min [–36 L/min to 23 L/min]). Conclusion: Glucagon alone provided no clinically important immediate bronchodilation in ED patients with asthma exacerbation. [Wilber ST, Wilson JE, Blanda M, Gerson LW, Meerbaum SO, Janas G. The bronchodilator effect of intravenous glucagon in asthma exacerbation: a randomized, controlled trial. Ann Emerg Med. November 2000;36:427-431.]" @default.
- W4239303575 created "2022-05-12" @default.
- W4239303575 creator A5017821095 @default.
- W4239303575 creator A5035278553 @default.
- W4239303575 creator A5038212533 @default.
- W4239303575 creator A5041214260 @default.
- W4239303575 creator A5051769604 @default.
- W4239303575 creator A5067285648 @default.
- W4239303575 date "2000-11-01" @default.
- W4239303575 modified "2023-09-26" @default.
- W4239303575 title "The bronchodilator effect of intravenous glucagon in asthma exacerbation: A randomized, controlled trial" @default.
- W4239303575 doi "https://doi.org/10.1016/s0196-0644(00)44407-0" @default.
- W4239303575 hasPublicationYear "2000" @default.
- W4239303575 type Work @default.
- W4239303575 citedByCount "8" @default.
- W4239303575 countsByYear W42393035752015 @default.
- W4239303575 countsByYear W42393035752016 @default.
- W4239303575 countsByYear W42393035752017 @default.
- W4239303575 countsByYear W42393035752020 @default.
- W4239303575 crossrefType "journal-article" @default.
- W4239303575 hasAuthorship W4239303575A5017821095 @default.
- W4239303575 hasAuthorship W4239303575A5035278553 @default.
- W4239303575 hasAuthorship W4239303575A5038212533 @default.
- W4239303575 hasAuthorship W4239303575A5041214260 @default.
- W4239303575 hasAuthorship W4239303575A5051769604 @default.
- W4239303575 hasAuthorship W4239303575A5067285648 @default.
- W4239303575 hasConcept C126322002 @default.
- W4239303575 hasConcept C142724271 @default.
- W4239303575 hasConcept C168563851 @default.
- W4239303575 hasConcept C204787440 @default.
- W4239303575 hasConcept C27081682 @default.
- W4239303575 hasConcept C2776042228 @default.
- W4239303575 hasConcept C2777014857 @default.
- W4239303575 hasConcept C2778563252 @default.
- W4239303575 hasConcept C2779306644 @default.
- W4239303575 hasConcept C2781018748 @default.
- W4239303575 hasConcept C2908646376 @default.
- W4239303575 hasConcept C42219234 @default.
- W4239303575 hasConcept C71924100 @default.
- W4239303575 hasConceptScore W4239303575C126322002 @default.
- W4239303575 hasConceptScore W4239303575C142724271 @default.
- W4239303575 hasConceptScore W4239303575C168563851 @default.
- W4239303575 hasConceptScore W4239303575C204787440 @default.
- W4239303575 hasConceptScore W4239303575C27081682 @default.
- W4239303575 hasConceptScore W4239303575C2776042228 @default.
- W4239303575 hasConceptScore W4239303575C2777014857 @default.
- W4239303575 hasConceptScore W4239303575C2778563252 @default.
- W4239303575 hasConceptScore W4239303575C2779306644 @default.
- W4239303575 hasConceptScore W4239303575C2781018748 @default.
- W4239303575 hasConceptScore W4239303575C2908646376 @default.
- W4239303575 hasConceptScore W4239303575C42219234 @default.
- W4239303575 hasConceptScore W4239303575C71924100 @default.
- W4239303575 hasIssue "5" @default.
- W4239303575 hasLocation W42393035751 @default.
- W4239303575 hasOpenAccess W4239303575 @default.
- W4239303575 hasPrimaryLocation W42393035751 @default.
- W4239303575 hasRelatedWork W2020308275 @default.
- W4239303575 hasRelatedWork W2033467955 @default.
- W4239303575 hasRelatedWork W2060349397 @default.
- W4239303575 hasRelatedWork W2109586110 @default.
- W4239303575 hasRelatedWork W2133080325 @default.
- W4239303575 hasRelatedWork W2186478762 @default.
- W4239303575 hasRelatedWork W2205572608 @default.
- W4239303575 hasRelatedWork W2287163345 @default.
- W4239303575 hasRelatedWork W2435058342 @default.
- W4239303575 hasRelatedWork W2586663018 @default.
- W4239303575 hasVolume "36" @default.
- W4239303575 isParatext "false" @default.
- W4239303575 isRetracted "false" @default.
- W4239303575 workType "article" @default.